Association between hyperlipidemia and prostatic enlargement : A case-control study

OBJECTIVE: A high-fat diet is associated with the development of benign prostatic enlargement (BPE), but whether hyperlipidemia is associated with BPE remains unclear. This study aimed to evaluate whether hyperlipidemia is a risk factor for the development of BPE.

MATERIAL AND METHODS: This study included 265 BPE patients with lower urinary tract symptoms (LUTS) and 248 age-matched healthy individuals without LUTS. The patient and control groups included in the study were compared in terms of fasting serum glucose, serum lipid values, prostate specific antigen (PSA), and prostate size measured by abdominal ultrasonography.

RESULTS: The prostate sizes of the patient and healthy control group were 59.4 ± 12.6 and 41.8 ± 11.1 ml, respectively (p = 0.007). It was observed that the mean PSA value of the patient group (2.33 ± 1.69) was statistically higher than that of the control group (1.21 ± 1.05) (p = 0.002). Total cholesterol and LDL-cholesterol were significantly higher and HDL-cholesterol was significantly lower among the patients compared to the controls. Prostate size had a negative correlation with HDL-cholesterol and a positive correlation with LDL-cholesterol and total cholesterol. Additionally, LDL-cholesterol and total cholesterol were independent risk factors for prostate enlargement.

CONCLUSION: This study indicates that increased levels of LDL-cholesterol and total cholesterol are significantly associated with the enlargement of the prostate. Hyperlipidemia may be one of the risk factors in the processes of prostatic growth and progression.

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:89

Enthalten in:

Urologia - 89(2022), 1 vom: 01. Feb., Seite 58-63

Sprache:

Englisch

Beteiligte Personen:

Erbay, Güven [VerfasserIn]
Ceyhun, Gökhan [VerfasserIn]

Links:

Volltext

Themen:

Aging
Benign prostate enlargement
Hyperlipidemia
Journal Article
Lipid
Lower urinary tract symptoms

Anmerkungen:

Date Completed 14.01.2022

Date Revised 30.04.2022

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1177/03915603211003401

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM323057748